成熟恒牙不可复性牙髓炎活髓切断术中牙髓血活性MMP-9浓度与预后的关联初探
SIP牙aMMP-9中位浓度显著高于正常牙髓牙(193.3 vs 52 ng/mL,P=0.0003),失败病例显著高于成功病例(512.4 vs 132.3 ng/mL,P=0.0015),aMMP-9对结局预测的ROC曲线下面积为0.9484。
要点
- SIP成熟恒牙牙髓血aMMP-9中位浓度显著高于正常牙髓牙。
- 活髓切断术失败病例aMMP-9浓度显著高于成功病例。
- aMMP-9可能作为预测活髓切断术结局的预后生物标志物。
核心结论
- 症状性不可复性牙髓炎成熟恒牙牙髓血aMMP-9浓度与活髓切断术结局显著相关,可能作为潜在预后生物标志物。
研究设计与样本
- 活髓切断术使用2.5%次氯酸钠止血、MTA盖髓、复合树脂即刻修复,术后6和12个月复诊,12个月评估结局。
主要发现
- 活髓切断术12个月成功率为88%。
- 正常牙髓牙牙髓血aMMP-9中位浓度为52(12-96)ng/mL,SIP牙为193.3(25.8-607.7)ng/mL,差异有统计学意义(P=0.0003)。
- 活髓切断术成功病例aMMP-9中位浓度为132.3(25.8-548.3)ng/mL,失败病例为512.4(334.8-607.7)ng/mL,差异有统计学意义(P=0.0015)。
- aMMP-9浓度与活髓切断术结局存在显著关联,ROC曲线下面积为0.9484(95%CI),提示预测判别能力优秀。
关键数值与推荐
- SIP牙临床诊断标准为症状性不可复性牙髓炎且根尖周指数(PAI)≤2。
- 活髓切断术成功定义为无症状且PAI≤2,失败定义为有症状或PAI≥3。
- 牙髓血aMMP-9浓度采用荧光测定法定量。
临床怎么用
- 对SIP成熟恒牙行活髓切断术前,可考虑检测牙髓血aMMP-9浓度辅助评估预后。
- aMMP-9浓度较高的SIP牙活髓切断术失败风险可能增加,需加强术后随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To investigate the correlation between the concentration of active-matrix metalloproteinases-9 (aMMP-9) in pulpal blood and the outcome of pulpotomy in mature permanent teeth with symptomatic irreversible pulpitis (SIP). METHODOLOGY: Forty permanent molar teeth with a clinical diagnosis of SIP and normal apical tissues with periapical index (PAI) score ≤ 2 and ten permanent teeth (8 molars and two premolars) with a diagnosis of normal pulp that required root canal treatment for prosthetic reasons from patients between the ages of 15-35 years were recruited. All clinical procedures were performed under local anaesthesia and rubber dam isolation. After access opening, the coronal pulp tissue was amputated up to the canal orifice. A 100 μL volume of the pulpal blood was collected using a micropipette and transported to the laboratory. Sodium hypochlorite (2.5 %) was used as a haemostatic agent, and mineral trioxide aggregate (MTA) was used as the pulp capping material. The tooth was restored with composite at the same visit. Teeth with normal pulps were treated with single-visit root canal treatment. Patients with pulpotomy were recalled at 6 and 12 months. Outcome assessment of teeth with pulpotomy was carried out at 12 months and was categorized as success (asymptomatic patients with PAI score ≤ 2) or failure (symptomatic patients or PAI score ≥ 3). Quantification of aMMP-9 in pulpal blood was achieved using a fluorometric assay. The following statistical analyses were performed to assess the data: t-test, Fisher's exact test, kappa coefficient, non-parametric test, Wilcoxon rank-sum test, Spearman rank correlation test and receiver operating characteristic curve (ROC). RESULT: The success rate of pulpotomy was 88 % at 12-months. There was a significant difference between the median concentrations of aMMP-9 in pulpal blood of teeth with normal pulps (52 (12-96) ng mL-1 :) and SIP (193.3 (25.8-607.7) ng mL-1 :) (P = 0.0003) and successful (132.3 (25.8-548.3) ng mL-1 :) and failed cases (512.4 (334.8-607.7 ng mL-1 :) (P = 0.0015) of MTA pulpotomy. A significant association was established between aMMP-9 concentration and outcome of pulpotomy. The area under the receiver operating characteristics curve (0.9484, 95%CI) suggested excellent discriminatory power of aMMP-9 concentration in pulpal blood to predict the pulpotomy outcome. CONCLUSION: The pulpal blood concentration of aMMP-9 was significantly associated with the outcome of pulpotomy in teeth with symptomatic irreversible pulpitis, where it may be used as a potential prognostic biomarker.
引用
- Sharma R, Kumar V, Logani A, et al. Association between concentration of active MMP-9 in pulpal blood and pulpotomy outcome in permanent mature teeth with irreversible pulpitis - a preliminary study. Int Endod J. 2020. PMID: 33128238. doi:10.1111/iej.13437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。